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Over 49,000 women each year in the UK are diagnosed with breast cancer making it 
the most prevalent cancer in women(1). Most primary breast cancers in the UK are 
diagnosed through two routes. The NHS Breast Screening Programme (NHSBSP) 
offers mammography every three years to women between the ages of 50 and 70. 
The breast screening services diagnose about a third of breast cancers. The 
remaining two-thirds of patients with breast cancer present, generally, to primary 
care, with symptoms, including a breast lump, nipple discharge, breast pain, and 
nipple inversion.  In the UK, demand for symptomatic breast services continues to 
increase annually, despite a relative plateau in the number of new cases of breast 
cancer diagnosed. From NHS Digital data (derived from hospital HES data), there 
were 612,619 first appointments at NHS breast clinics in 2017-18, an increase from 
591,800 in 2016-17, and 583,676 in 2015-16. (2) 
 
Breast cancer survival depends on the stage of the disease at diagnosis, the 
treatment received, and the biology of the tumour. More than 90% of women 
diagnosed with early breast cancer survive for at least five years, and 78% survive 
for ten years. In contrast, only 13% of those diagnosed with advanced disease 
survive for more than five years 
  
Currently, there are three topics of interest and changing practice in  the area of 
breast cancer diagnosis and management that are relevant to primary care;  the use 
 
of neoadjuvant chemotherapy, genomic Markers and profiling in breast cancer and: 
Breast Implant Associated Anaplastic Large Cell Lymphoma a new disease entity. 
An update on each area follows. 
 
Use of Neoadjuvant Chemotherapy  
Early breast cancer is traditionally treated with surgery first and adjuvant 
(postoperative) systemic treatments (chemotherapy, endocrine treatment, targeted 
treatments) and radiotherapy   will then be considered as strategies to reduce the 
risks of both systemic and local recurrence. Adjuvant treatment recommendations 
are based on stage and biology of the tumour as well as patient’s fitness. 
 
 New adjuvant therapy refers to the systemic treatment of breast cancer prior to 
definitive surgical treatment, pre-operative therapy.  Typically neoadjuvant treatment 
has taken the form of chemotherapy (NACT), although there is increased interest in 
expanding the role of neoadjuvant endocrine treatment in certain situations. 
 One of the goals of NACT is to downstage the breast tumour which may permit less 
extensive surgery on the breast and the axilla  avoiding  the risks associated with 
breast reconstruction enabling  the  patient able to undergo breast conserving 
surgery instead of mastectomy, improving cosmetic outcomes and reducing 
postoperative complications such as lymphoedema.   
Also, NACT also permits evaluation of the effectiveness of systemic treatment which 
can then be used to guide decision making about adjuvant, post-operative, 
treatment.  The response of the cancer to neoadjuvant therapy is a strong prognostic 
 
factor for recurrence especially in triple negative breast cancer and Her 2 positive 
breast cancer.  Emerging studies suggest the NACT may allow a tailored approach 
to systemic treatments after breast surgery.  In particular, studies have shown 
addition of capecitabine as adjuvant treatment in women with triple negative breast 
cancer and residual cancer after NACT (3)or adding transtuzumab emtansine in 
women with Her 2 positive breast cancer and residual cancer after NACT  can 
improve long-term outcomes.  (4) 
Although was hypothesised that overall survival may be improved by neoadjuvant 
therapy due to earlier initiation of systemic treatment in patients of high risk of 
recurrence randomised trials have demonstrated equivalent survival for pre and 
postoperative chemotherapy. 
The use of new or adjuvant chemotherapy is associated with an increased frequency 
of breast conserving surgery (65% versus 49%).  It was also associated with 
increased risk of local recurrence (15 years local recurrence rate 21.4% versus 
15.9%) which has been attributed to the increased use of breast conserving 
surgery.(5) 
 Since the early trials have been many advances in selecting patients for 
neoadjuvant treatment as well as demonstration of benefit of selecting subsequent 
treatment based on response.   
In summary neoadjuvant systemic treatment could offer an advantage for a selected 
group of patients, although for the majority of breast cancers surgery first remains 
the recommended treatment strategy. 
 
Discussion between members of breast multidisciplinary team and patient 
involvement in decision making about treatments are paramount for appropriate 
patient selection 
 
Genomic Markers and Profiling: New NICE Guidance 
 The widespread application of adjuvant systemic therapy has reduced mortality from 
breast cancer. 
Prognostic factors (provide information on risk and clinical outcomes independent of 
therapy) and predictive factors (provide information of likelihood of response to a 
given treatment) are used in making treatment decision on adjuvant systemic 
treatments.  Several factors in breast cancer are both prognostic and predictive. 
Traditionally patient related factors (such as age), stage (tumour size, nodal 
involvement) and pathological factors (such as oestrogen receptor and Her 2 
expression, grade) have been used as prognostic and/or predictive factors in 
advising on adjuvant treatments.  Unfortunately even with taking this information into 
consideration, treatments cannot be rationalised with complete accuracy with some 
patients are over treated and some patients are under treated.  
 The emergence of genomic techniques and the ability to measure expression of 
genes has led to the development of biological based tests to aid recommendation 
for adjuvant systemic treatments. 
 
 
New NICE Guidance was published in 2019 about genomic markers to tailor 
oncology decision making regarding chemotherapy (REF). EndoPredict , Oncotype 
DX Breast Recurrence Score and Prosigna are recommended as options for guiding 
adjuvant chemotherapy decisions for people with oestrogen receptor (ER)-positive, 
human epidermal growth factor receptor 2 (HER2)-negative and lymph node (LN)-
negative/lymph node micro metastasis only early breast cancer.(6) 
 Oncotype DX breast recurrence score is the most well validated assay to identify 
patients who are most and least likely to derive benefit from adjuvant chemotherapy.  
At this time, it is indicated for women with node negative or node micro metastasis 
only, oestrogen receptor positive and Her 2 negative breast cancer. Work to define 
Oncotype Dx role in patients with 1-3 nodes involved is ongoing. 
 After breast surgery and when all the above information is available, the case is 
discussed in multidisciplinary team meeting and recommendations are made. 
Oncologists will see the patient to discuss the risks from the tumour and possible 
benefits from systemic treatment so informed treatment decisions are undertaken. 
 
New Disease Entities: Breast Implant Associated Anaplastic Large Cell 
Lymphoma 
Practitioners in primary care should also be aware of a new clinical entity, breast 
implant associated anaplastic large cell lymphoma (BIA- ALCL).Breast implant-
associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon peripheral T 
cell lymphoma arising around textured-surface breast implants placed for either 
reconstructive or cosmetic indications.  The incidence of ALCL in patients who have 
 
had textured implants inserted is in the order of 1 in 7000. The association of breast 
implants with a cancer of the immune system has created understandable concern 
amongst patients, plastic and breast surgeons, and oncologists. (7) 
Initial studies suggest that BIA-ALCL follows a relatively indolent course in most 
patients. Those patients with early stage disease have an excellent prognosis. 
Reports of disseminated cancer and deaths attributed to the disease emphasise the 
importance of appropriate surveillance, timely diagnosis, and adequate treatment. 
BIA-ALCL is a rare condition; clinicians must maintain a high index of suspicion 
particularly regarding the development of a new seroma around an existing breast 
implant in which case the diagnosis is usually made by aspiration of the diagnostic 
aspiration of the seroma. Most cases present approximately ten years after implant 
placement, although earlier or later presentations can be seen. Practitioners in 
primary care need to be aware of this condition. Any patient presenting with new 
swelling, diffuse or localised, around an existing implant needs to be referred to a 
one stop breast clinic for a full triple assessment. 
 
Considerable advances have been made in tailoring the treatment of patients with 
breast cancer, to allow treatment escalation for high risk disease and treatment de-
escalation for low risk good prognostic tumours.  This progress requires, as does the 
diagnosis of ACLC, careful multidisciplinary team working between oncologists, 
surgeons, radiologists and pathologists to deliver the highest possible standards of 
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